DEC 10, 2016 11:00 AM PST

New Immunotherapy Prevents Relapse for Leukemia Survivors

WRITTEN BY: Kara Marker
For high-risk cancer patients with acute myeloid leukemia (AML), oncologists are interested in supplementing bone marrow transplants with a new, experimental treatment with genetically engineered T cells. The first study was conducted in a small number of patients, but scientists believe that there will soon be more studies like it done due to the successful results.
 A high power view of AML with multilineage dysplasia. Source: American Society of Hematology
From the Fred Hutchison Cancer Research Center, scientists took in 12 patients with high-risk AML who had received a bone marrow transplant that put them in remission. The patients were all considered to be high-risk due to genetic factors or other disease characteristics that reduced the chance of remaining in remission following a bone marrow transplant. Following the transplant procedure, researchers continued with a treatment of genetically engineered T cells.
 
T cells from the treatment were extracted from each patient’s own transplant donor. After extraction, the cells were genetically engineered to express receptors on their cell surface that recognize very specifically a target molecule, called WT1. This molecule is much more highly concentrated in leukemia cells than non-cancerous cells, which helps the T cells distinguish tumor cells from healthy cells.
 
After a median follow-up of time of two years, all 12 of the study’s participants were still in remission. The combination of a bone marrow transplant and T cell therapy is what study leader Dr. Aude Chapuis believes is the secret to the success of the treatment. It “might actually be helping patients who have a high risk of relapsing,” she explained.
 
The findings observed in this study differ from what scientists saw in previous studies where AML patients received a transplant but no genetically engineered T cells. Instead of remaining in remission, around 25 percent of the transplant-only patients relapsed within 10 months.
 
Chapuis’s study was just the first trial using this strategy. Their experimental group was indeed small, but studying high-risk group of AML patients provided them the most extreme case to prove that their treatment combination would be effective.
 
Chapuis, who treats cancer patients at Seattle Cancer Care Analysis, says that her source of inspiration for the work that she does is the patients she sees everyday undergoing bone marrow transplants. “I’m always horrified by the intense treatment that we inflict on bone marrow transplant patients and the hardship that we make them go through,” Chapuis said. “I really think we can do better. That’s why I’m doing this.”
 

 
Source: Fred Hutchison Cancer Research Center
 
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
China Begins Trials for Antiviral Drug to Tackle Coronavirus
So far, coronavirus has infected over 31,493 people globally, and has killed 638. Although 1,563 people have reportedly ...
FEB 19, 2020
Immunology
FEB 19, 2020
Rainbow trout hold the key to unravelling immunological mysteries
What do the gut microbiome, antibodies, and rainbow trout have in common? A lot, says researcher J. Oriol Sunyer from th ...
MAR 19, 2020
Drug Discovery & Development
MAR 19, 2020
Could a 1949 Malaria Drug Treat COVID-19?
In the race to halt the current coronavirus pandemic, scientists, health experts and even Elon Musk are considering chlo ...
APR 22, 2020
Immunology
APR 22, 2020
Scientists Engineer Custom Antiviral Receptors to Fight COVID-19
The best offense may be a good defense in the fight against COVID-19. Researchers from the Duke-NUS Medical School are e ...
MAY 07, 2020
Cell & Molecular Biology
MAY 07, 2020
How the Function of a Critical Immune Cell is Related to Metabolism
This work suggests that it may be possible to dampen autoimmunity or promote an immune attack on cancer through a bioche ...
MAY 21, 2020
Drug Discovery & Development
MAY 21, 2020
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repu ...
Loading Comments...